3,6-Dihydrochamazulene is an azulene-related hydrocarbon found in some blue tansy, wormwood, and related Asteraceae oils. The live evidence base is much thinner than for chamazulene itself: public sources firmly support identity data, repeated GC-MS occurrence, and a role as a chamazulene-related transformation or co-occurring marker, but there is little direct standalone pharmacology or safety literature for the isolated compound. For AromaForge, it is best framed as a blue-oil chemistry marker with limited constituent-specific bioactivity evidence.
Chemical identity and composition
NIST and PubChem agree on the formula C14H18 and CAS 18454-88-1 for 3,6-dihydrochamazulene. Recent chamazulene photodegradation work also identifies dihydrochamazulene as a reduction product formed during chamazulene photo-oxidative transformation, which helps explain why azulene-rich oils and stability discussions often mention the pair together.
Aroma and practical use
- Use the recorded blue-oil associated, herbal, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
blue tansy occurrence above five percent
A 2021 blue tansy composition study reported 3,6-dihydrochamazulene at 5.2%, placing it among the oil's constituents above 5% alongside sabinene, camphor, chamazulene, alpha-phellandrene, and p-cymene.
Measured: identification among major constituents
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
wormwood geographic variability marker
A 2025 full-text wormwood study found 3,6-dihydrochamazulene elevated in both Cogne samples and quantified it as the second main component there, at 10.75% in vegetative-stage oil and 17.48% in flowering-stage oil.
Measured: high abundance linked to one geography
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety monograph or dedicated fragrance safety assessment for isolated 3,6-dihydrochamazulene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because the accessible literature is dominated by occurrence chemistry and chamazulene transformation work, archive copy should avoid strong use-level or toxicology claims for the isolated constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Chamazulene-rich systems can undergo light- and oxygen-driven degradation; that context is relevant here because dihydrochamazulene appears in chamazulene photochemistry discussions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
disproportionation product of chamazulene
A 2024 chamazulene photodegradation study reports dihydrochamazulene as a product formed when chamazulene undergoes disproportionation, with reduction by addition of two hydrogen atoms paired with oxidized chamazulene formation.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Most accessible literature treats 3,6-dihydrochamazulene as a component of blue-oil mixtures or as a chamazulene-related product rather than as a standalone tested ingredient.
- The antiparasitic Artemisia paper links activity to fractions where dihydrochamazulene was a main component, but it does not establish isolated-compound causality strongly enough for direct benefit claims.
- No constituent-specific human clinical or dedicated toxicology paper for isolated 3,6-dihydrochamazulene was verified in this pass.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.